Hospitals Eligible For Discounted Drugs Would Increase Under Legislation
This article was originally published in The Pink Sheet Daily
Executive Summary
A bill being drafted by the Senate Republican leadership would facilitate hospital participation in the federal Sec. 340B drug discount program through model contracts and relaxation of inventory management requirements, Public Hospital Pharmacy Coalition General Counsel von Oehsen says.
You may also be interested in...
340B Report Conclusions Valid Despite Underlying Data Problems, IG Says
HHS Office of Inspector General withdraws its report on 340B drug pricing because of incorrect data mistakenly supplied by CMS. OIG plans to conduct a wider review of the 340B program before reissuing the report.
340B Drug Pricing Data Should Be Listed On Secure Website, IG Recommends
The HHS Inspector General estimates that 340B entities paid an additional $41.1 mil. on outpatient drugs in September 2002 because they could not verify the ceiling price. HRSA has begun updating contact information and 340B participation status in real-time.
NME Slowdown Shows Market Pressure On Me-Toos, Not FDA Caution – Lutter
DURHAM, N.C. - The decline in FDA's tally of new molecular entity approvals stems from fewer approvals of non-innovative products in recent years, while approvals of truly innovative products has largely held steady, according to FDA Deputy Commissioner for Policy, Planning and Preparedness Randall Lutter